In the first half of 2026, the Krka Group generated revenue of €1,119.3 million, up 7% year on year, yielding €260.2 million net profit, up 5%. The Supervisory Board of Krka discussed the Krka Group and Krka business report for the first half of 2026 at their regular meeting yesterday.
President of the Management Board and Chief Executive Officer Jože Colarič commented:
“As already reported at the Annual General Meeting (AGM) on 9 July, we performed very successfully in the first half of this year. We increased product and service sales in five sales regions and most of our markets, achieving record half-year sales. Our revenue totalled €1,119.3 million, a 7% increase year on year. Most of our operating results improved as well. EBITDA increased to €357.5 million, while EBITDA margin stood at 31.9%.”
He accentuates that EBIT reached €309.2 million, up 20%, and net profit increased as well, exceeding €260 million.
Jože Colarič: “We expanded our product portfolio with six prescription pharmaceuticals and one product for companion animals. We continued all key investment projects in Slovenia and abroad to increase the manufacturing capacity and strengthen our vertically integrated business model. We allocated €52.8 million to investments. At Krka, we remain committed to implementing our long-term dividend policy.”
“Today, Krka shareholders are receiving a 2025 dividend of €9.10 gross per share, up just over 10% year on year, marking the 27th consecutive annual dividend increase. The AGM approved all proposed resolutions and authorised the Management Board to implement a new three-year share buyback programme. We will publish our nine-month results together with the 2026 business performance estimate and the 2027 business plan on 12 November 2026. Considering our performance in the first half of the year, we expect to meet our 2026 annual plan targets by the end of the year,” concludes Jože Colarič
